Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in ParticipantsWith IgG4-Related Disease

NCT04520451 is registered in ClinicalTrials.gov with Principia Biopharma, a Sanofi Company as lead sponsor.

NCT NCT04520451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04520451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in ParticipantsWith IgG4-Related Disease
Lead sponsor
Principia Biopharma, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
August 22, 2020
Completion date
October 15, 2024
Enrollment
27 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin g4 related disease